RecruitingPhase 1NCT06685809

A Phase 1 Study of FZ008-145 in Healthy Subjects.

A Phase 1 Study Assessing Safety, Tolerability, Pharmacokinetics and Physiological Response (Pain Tolerance) to Single and Multiple Ascending Doses of FZ008-145 in Healthy Subjects.

Sponsor

Guangzhou Fermion Technology Co., LTD

Enrollment

190 participants

Start Date

Nov 25, 2024

Study Type

INTERVENTIONAL

Conditions

Healthy

Summary

The study will be conducted in 5 parts: Part A (single ascending dose \[SAD\] in solution formulation), Part C (food effect \[FE\]), Part D (cold pressor test \[CPT\] to evaluate pain tolerance following single dose), and Part E (multiple ascending dose \[MAD\] in tablet formulation).

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called FZ008-145 Tablet, a drug called FZ008-145 solution, and others for people with healthy. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.